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Summary: The aminopeptidases constitute a group of enzymes with closely related activities. In clinical
chemistry the analysis of the aminopeptidases and of their multiple forms in serum has for a long time been
hindered by considerable confusion concerning their identification, and by a lack of characterization. This is
in part due to the often large, and sometimes overlapping substrate specificities of the aminopeptidases.
This paper reviews the biochemical properties of the different aminopeptidases, the specificities of the assays
used for their analysis in serum, some aspects of their multiple forms — which are especially known to occur
for alanine äminopeptidase (EC 3.4.11.2) — and the importance of the determination of aminopeptidases
and their multiple forms in clinical chemistry.
Introduction
Aminopeptidases are enzymes which hydrolyse pep-
tide bonds near the N-terminal end of polypeptides.
They can be subdivided into aminopeptidases which
hydrolyse the first peptide bond (aminoacyl-peptide
hydrolases and iminoacyl-peptide hydrolases) and
those which remove dipeptides from polypeptide
chains (dipeptidyl-peptide hydrolases). Some pepti-
dases act only on dipeptides or tfipeptides and may
also be considered as aminopeptidases.
Aminopeptidases are present in many human tissues
and body fluids. They are generally zinc-metalloen-
zymes. They are thought to be involved in the metab-
olism of proteins and various peptide hormones.
According to the method and conditions of analysis,
several forms of äminopeptidase activity can be de-
termined in human plasma and other tissues. This
heterogeneity has several causes:
— different gene loci; several proteins are synthesized
with an äminopeptidase activity. These enzymes
differ in immunological properties, substrate spec-
ificities, pH optima, activators, etc. A list of some
human aminopeptidases acting on polypeptides is
given in table 1.
— substrate specificities; the different aminopepti-
dases have a closely related enzymatic activity with
sometimes broad specificities. These specificities
overlap, so that many natural and synthetic sub-
strates may be hydrolyzed by more than one en-
zyme. This is especially the case when the substrate
is a polypeptide.
— post-translational modifications; these are espe-
cially known to occur for alanine äminopeptidase.




aggregation with other proteins or phospho-
lipids.
Taking some of these aspects into consideration, we
shall discuss the main human aminopeptidases of
interest in clinical chemistry, excluding dipeptidases
and dipeptidyl-peptide hydrolases.
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basic pH optimum; ' '
does not hydrolyse chromogenic substrates
some activation by Co2+
no inhibition by bestatin and amastatin;
heat labile
activated by Ca2+;
for glu-substrates also activated by Ba2+
















acts on tripeptides only;
no inhibition by amastatin
act on dipeptides only
remove dipeptides
*AA = amino acid
Aminopeptidases from Different Gene Loci
Leucine aminopeptidase
Leucine aminopeptidase ( -aminoacyl-peptide hydro-
lase (cytosol), EC 3.4.11.1) was discovered by Lin-
derstrom-Lang (1) in 1929. It hydrolyses preferentially,
but not exclusively, peptide bonds adjacent to an N-
terminal leucine residue, as in leucinamide and leu-
cylglycine (2, 3). Leucine aminopeptidase has mainly
been studied in bovine lens and pig liver (4 — 7). It is
a zinc-metalloenzyme, generally localized in cytosolic
subfractions, and it is present in liver, lung, stomach,
kidney, intestine, serum and leukocytes, as well as
other tissues (3, 8, 9).
Leucine aminopeptidase is immunologically distinct
from alanine aminopeptidase (8). Lederne et al. (10)
purified two forms of leucine aminopeptidase activity
from human liver which differed in their isoelectric
points. Kohno et al. (3) recently purified the leucine
aminopeptidase from liver cytosol by immunoaffinity
chromatography. Liver leucine aminopeptidase is a
hexamer (MT 360 000) consisting of three dimers with
two different subunits each (Mr 53 000 and 65 000).
Human leucine aminopeptidase has an optimum at
pH 10, is typically activated by Mg2+ and Mn2+,
and inhibited by Zn2+, Co2*, complexing agents,
bestatin and amastatin. Human liver leucine amino-
peptidase was not found to hydrolyse the chromo-
genic substrates leucyl-4-nitroanilide, leucyl-ß-na-
phthylamide or alanyl-4-nitroaiiilide (3, 10).
Alanine aminopeptidase
Alanine aminopeptidase (oc-aminoacyl-peptide hydro-
lase (microsomal), EC 3.4.11.2, arylamidase, amino-
peptidase M, aminopeptidase N) is probably the ami-
nopeptidase which has been studied most extensively.
Alanine aminopeptidase hydrolyses preferentially nat-
ural or synthetic substrates with an N-terminal alan-
ine residue. Other amino acids, especially leucine, may
also be removed hydrolytically, with the exception of
proline. The lowest Km values are found with methi-
onine-substrates (2, 11 — 16).
Alanine aminopeptidase may hydrolyse several bio-
logically active peptides, e. g. met-lys-bradykinin and
lys-bradykinin (17). Alanine aminopeptidase from rat
brain and hog aorta are capable of hydrolysing (riiet5)-
enkephalin and (Ieu5)-enkephalin (18—20). In enzyme
assays the most frequently used substrates are 4-
nitroanilides and ß-naphthylamides of alanine and
leucine.
Human alanine aminopeptidase has been found to be
ptesent in virtually all tissues Studieid, with relatively
high specific activities in the brush border membranes
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of kidney proximal tubules and intestine and in bile
canalicular membranes (21 —27). Human alanine ami-
nopeptidase has been purified from liver (8, 12, 28 —
30), kidney (11, 31-33), intestine (13, 34, 35), pla-
centa (31, 36) and blood plasma (37, 38). Relative
molecular mass estimations of the enzyme range from
about 150000 (39—41) (obtained by electrophoresis
of the non-purified serum enzyme) to about 240 000
for purified enzymes by gel filtration (16, 28, 42).
Starnes & Belial (28) noticed an equilibrium between
al lS 000 monomeric form and a 235 000 dimeric form
of liver alanine aminopeptidase in dilute salt solutions.
Each 118000 unit contains one atom of zinc (43).
Alanine aminopeptidase is a glycoprotein, with a car-
bohydrate part presenting between 12 and 21% of its
mass, depending on the tissue source (11, 28, 31, 37).
Alanine aminopeptidase may contain a large number
of sialic acid groups, which explains the rather low
isoelectric points, from pH 3.3 — 3.6 (liver, serum en-
zyme) to pH 4.7 (kidney, pancreas) (8, 28, 40, 44).
Alanine aminopeptidase is generally found in mem-
brane fractions obtained by ultracentrifugation. It can
be solubilized from tissues by autolysis or by proteo-
lytic enzymes such as papain, bromelain and trypsin,
or by extraction with detergents (22, 25). Studies on
alanine aminopeptidase of pig intestine have shown
that alanine aminopeptidase is anchored in the mem-
brane by a small hydrophobic polypeptide which is
removed by the solubilizing enzymes (45, 46).
Alanine aminopeptidase is activated by Co2+. Some
other metal ions, coinplexing agents and amino acids
are inhibitors (13, 33, 37, 43, 47). A very potent
inhibitor is amastatin and, to a lesser degree, bestatin
and puromycin (15, 37). The pH optimum of alanine
aminopeptidase is buffer- and substrate-dependent,
generally between pH 6.5-8.5 (48-50).
Cystyl aminopeptidase
Cystyl aminopeptidase (oc-aminoacyl-peptide hydro-
lase, EC 3.4.11.3, pxytocinase) can be detected in
serum and amniotic fluid during pregnancy (51 — 53).
The physiological substrate of cystyl aminopeptidase
appears to be oxytocin, a peptide with an N-terminal
cystine, and which induces uterine contraction. Cystyl
aminopeptidase is mainly localized in placental lyso-
somes (54).
Lalu et al. (55) compared the biochemical character-
istics of eystyl aminopeptidase preparations purified
from placenta and maternal serum. The relative mo-
lecular mass of both enzymes was 320 000, which is
the same as found by Oya et al. (39) for serum cystyl
aminopeptidase. The most rapidly hydrolysed sub-
strate was leucyl-4-nitroanilide, followed by leucyl-ß-
naphthylamide and S-benzyl-cysteyl-4-nitroanilide.
The preparations also showed lysyl-ß-naphthylami-
dase activity, while the Fmax of cystyl-di-ß-naphthyl-
amide hydrolysis was only 7% of that of leucyl-ß-
naphthylamide. One difference between the two pur-
ified preparations was the relatively high alanyl-ß-
naphthylamidase acitivity of the placental enzyme
preparation. The preferential hydrolysis of leucyl-
arylamides by cystyl aminopeptidase is a general find-
ing (36, 38, 40, 48, 56). Some characteristic properties
of cystyl aminopeptidase which distinguish it from
some other aminopeptidases, are its heat lability and
resistance to methionine, bestatin and amastatin in-
hibition (15, 57).
It is generally accepted that cystyl aminopeptidase in
serum is derived from placental lysosomes (54, 55,
58), but comparisons of studies on placental and
serum cystyl aminopeptidase are hindered by the fact
that the placenta contains several other soluble and
membrane-bound aminopeptidases (59, 60). The sub-
strate specificities are rather broad, and pH optima
and the action of effectors are often found to be
substrate- or tissue-dependent (55, 61, 62). It has been
shown that the placenta also contains aminopeptidase
A (63) and microsomal alanine aminopeptidase,
which is immunologically different from serum cystyl
aminopeptidase but identical with kidney alanine ami-
nopeptidase (31, 36). Several groups have observed a
placental enzyme which shares with cystyl aminopep-
tidase its insensitivity to methionine, its heat lability
and the capacity to hydrolyse cystyl-di-ß-naphthylam-
ide, while it has in common with alanine aminopep-
tidase its microsomal localization and electrophoretic
mobility (52, 54, 58). It is also present in meconium-
contaminated amniotic fluid and colostrum (52, 64).
A possible explanation for these findings would be
some hydrolysis of cystine substrates by microsomal
alanine aminopeptidase (65), but the enzyme activity
was not found in normal or pregnancy serum.
It is clear that more immunological studies are needed
to identify further the various aminopeptidase activ-
ities in the placenta and in pregnancy serum.
Other aminopeptidases
Some other aminopeptidases have been detected in
humans, sometimes in serum, but for most of these
the clinical interest has hardly been explored. They
are summarized beneath, since they may gain interest
and are possible sources of interference in the various
enzyme assays.
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Tripeptide aminopeptidase
Tripeptide aminopeptidase (a-aminoacyl-dipeptide
hydrolase, EC 3.4.11.4) only acts on the N-terminal
peptide bond of tripeptides. Few studies have been
conducted on the human enzyme. Kanda et al. (66)
found the enzyme to be widely distributed in cytosolic
subfractions of human tissues such as liver, intestine,
kidney, brain and lymphocytes. Usual substrates for
tripeptide aminopeptidase are leucyl-glycyl-glycine
and triglycine. Tripeptidases from animal tissues gen-
erally have a relative molecular mass between 50000
and 70000, with a neutral pH optimum, and are
inhibited by bestatin (67). Amastatin is not an inhib-
itor; this property has been used to distinguish tri-
peptide aminopeptidase activity in serum from other
aminopeptidases (68).
Aminopeptidase A
Aminopeptidase A (L-a-aspartyl (L-a-glutamyl)-pep-
tide hydrolase, EC 3.4.11.7, angiotensinase A) specif-
ically hydrolyses N-terminal aspartyl or glutamyl res-
idues from peptides or synthetic substrates (69). A
biological substrate is angiotensin, which possesses an
N-terminal Asp residue. This enzyme might therefore
also be called aspartyl aminopeptidase. The enzyme
has been purified from human placenta and preg-
nancy serum. It is present in various reproductive
organs (63, 70, 71). The relative molecular mass of
the human serum enzyme has been estimated as
260000. Aspartyl aminopeptidase is characteristically
activated by Ca+ + with the substrates glu-ß-naphthyl-
amide and asp-ß-naphthylamide. Hydrolysis of glu-
ß-naphthylamide but not of asp-ß-naphthylamide is
also activated by Ba++ ions. Activity towards leu-ß-
naphthylamide is absent and is very low towards ala-
ß-naphthylamide (70).
Aminopeptidase P
Aminopeptidase P (EC 3.4.11.9) occupies a special
place in this group of aminopeptidases, since it is able
to split N-terminal peptide bonds with a secondary
proline residue (72). Natural substrates are possibly
bradykinin and substance P (73). The enzyme has
been purified from human lung (74). The relative
molecular mass was estimated as 188000. The study
of Appel (75) on human serum proline arylamidase
seems to refer to a dipeptidase, proline aminopepti-
dase (EC 3.4.13.8).
Aminopeptidase B
Aminopeptidase B (EC 3.4.11.6) shows a specificity
for N-terminal lysyl and arginyl amino acids. It has
been purified from the cytosolic fraction of human
liver and skeletal muscle. (12, 76). The relative molec-
ular mass of human aminopeptidase B was estimated
as 72000. It is an unstable, thiol-dependent enzyme.
It hydrolyses preferentially, but not exclusively, di-
peptides. Aminopeptidase B acts on synthetic lysyl-
or arginyl-substrates, but not on ala-ß-naphthylamide
or leu-ß-naphthylamide. The enzyme shows a re-
markable activation by Cl" or Br" ions (12, 76). It
is inhibited by chelating agents and bestatin (76, 77).
Substrates and Methods of Analysis of Aminopepti-
dases from Serum
Leucine aminopeptidase
As mentioned above, leucine aminopeptidase does not
hydrolyse the chrompgenic substrates leucyl-4-ni-
troanilide and leucyl-ß-naphthylamide (3, 10, 78).
Leucine aminopeptidase activity is most often meas-
ured with the substrate leucinamide, which it hydro-
lyses to leucine and free ammonia (79). For the assay
of purified enzyme preparations, the decrease in ab-
sorbance may be measured directly at 238 nm (80).
Several groups have proposed methods in which the
liberated NH3 is detected. Plaquet et al. (81) and
Tamura et al. (82) used the reaction of Berthelot with
nitroprusside for the determination of leucine ami-
nopeptidase in human serum and rat plasma, respec^
tively. Continuous monitoring assays have been de-
scribed by Hafkenscheid & Kohler (83) and by Kanno
et al. (84). In their methods the liberated ammonia
reacts with 2-oxoglutarate in the presence of gluta-
mate dehydrogenase. The decrease in NADPH con-
centration, which is used in the reaction, is measured
at 340 nm.
Takamiya et al. (85) proposed a method in which the
leucine generated by the hydrolysis of leucinamide or
leucyl peptides is reduced by the enzyme leucine de-
hydrogenase. The NADH formed in the reaction is
measured at 340 nm.
Despite the frequent use of leucinamide as substrate
for leucine aminopeptidase, it seems not to be hydro-
lysed specifically by this enzyme only (50). Plaquet et
al. (81) found two forms of leucinamidase activity in
serum with different pH optima. The enzyme with a
neutral pH optimum was inhibited by Mg2+ and was
predominant in normal sera. Similarly, Kanno et al.
(84) showed by electrophoresis that there are two
leucinamidase bands in human serum. One of the two
forms also hydrolysed leucyl-4-nitroanilide and was
thus an arylamidase, propably alanine aminopepti-
dase.
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Plaquet et al. (81) eliminated the neutral activity by
performing the reaction at pH 9 in the presence of
Mg2H~ ions, which activates leucine aminopeptidase
and inhibits alanine aminopeptidase.
Dependence of substrate specificity on pH was also
found by Haschen et al. (86) in an assay with leucyl-
hydrazide as substrate and /7-dimethylaminobenzal-
dehyde as staining agent, and by Fleisher et al. (87)
with leucyl-glycine as substrate. Like leucinamide,
these substrates were also susceptible to hydrolysis by
alanine aminopeptidase at neutral or weakly basic
pH, and the assays were performed at pH 10.
Although the methods with an enzymatic indicator
reaction have the advantage that they may be used
in an automated continuous assay, they have to be
performed at a lower pH (8.2—8.3). Alanine amino-
peptidase is still active at this pH, which may explain
why a good correlation between leucinamide and leu-
cyl-4-nitroanilide hydrolysing activities has been ob-
served for some groups of samples (83, 85). Interfer-
ence by alanine aminopeptidase may also explain the
difference in upper reference limits which has been
observed with the methods at basic pH [12 U/l, (81)
and 1.6 U/l (86)] and a continuous method [65 U/l,
(83)].
Other substrates, which have been used for the detec-
tion of leucine aminopeptidase, are leucyl-glutamic
acid by Kusukabi (88) with an indicator reaction on
the liberated glutamate, leucylglycine with a ninhydrin
reaction by Fleisher et al. (89), and the synthetic
compound phe-3-thia-phe by Hwang et al. (90). After
enzymatic hydrolysis of this substrate, the thiol group
is released and stained with Ellman's reagent. The
authors found a 20-fold activity of leucine aminopep-
tidase as compared to alanine aminopeptidase for this
substrate, but the enzyme sources were not stated. A
disadvantage was some inhibition of leucine amino-
peptidase by Ellman's reagent.
Alanine aminopeptidase
The synthetic substrate leucyl-ß-naphthylamide was
used for the first time thirty years ago by Goldberg &
Rutenburg (91, 92) in what was thought to be the
analysis of leucine aminopeptidase. Later it became
clear that this substrate and leucyl-4-nitroanilide,
which was introduced in 1962 by Tuppy et al. (93),
were not hydrolysed by leucine aminopeptidase, but
by another enzyme (78, 87, 94), which furthermore
hydrolysed alanyl-substrates faster than leucyl-sub-
strates (48, 94, 95). The name alanine aminopeptidase
was proposed 20 years ago for this enzyme by Rehfeld
et al. (96). However, the use of leucyl-substrates for
the detection of alanine aminopeptidase has continued
along with the designation of alanine aminopeptidase
as leucine aminopeptidase, leucine arylamidase or leu-
cyl-ß-naphthylamidase, which has led to a certain
confusion.
The most frequently used method with leucyl-4-ni-
troanilide as substrate appears to be that of Nagel et
al. (97). An optimized assay has been recommended
by the German Society for Clinical Chemistry
(DGKC) (98). This method with a high substrate
concentration was further modified by Haflcenscheid
& Dijt (99).
The liberated nitroaniline is strongly coloured, which
makes continuous monitoring possible. The product
of the hydrolysis of leucyl-ß-naphthylamide, ß-
naphthylamine, is only weakly coloured. It may be
measured by fiuorimetry, but generally a coupling
reaction with a diazonium salt is used.
A drawback of the use of leucyl substrates is the fact
that they are the preferential substrates of cystyl ami-
nopeptidase, which hydrolyses them even better than
synthetic cysteine substrates, and that their use con-
tributes to the confusion with leucine aminopeptidase.
Tokioka-Terao et al. (100) developed a radioimmu-
noassay of human serum alanine aminopeptidase.
They found alanine aminopeptidase protein concen-
trations to correlate well with activity towards alanyl-
ß-naphthylamide in normal samples and in cases of
hepatobiliary disease. However, they found some in-
crease in enzymatic activity with this substrate — and
still much more with leucyl-4-nitroanilide — in preg-
nancy sera, while alanine aminopeptidase protein con-
centrations were the same as in non-pregnant women.
Hence, the increases measured with these substrates
are due to cystyl aminopeptidase in serum. Yet, no
increase in alanyl-4-nitroanilide hydrolysing activity
has been noticed in pregnancy sera (48, 101). This
would indicate a better specificity of alanyl-4-nitroan-
ilide than of alanyl-ß-naphthylamide, but this remains
to be confirmed.
There is now a certain agreement on the use of alanyl-
4-nitroanilide as substrate for determination of alan-
ine aminopeptidase activity in serum and urine (48,
49, 101 — 105). It has the advantage of specificity, it
has good solubility, and because of the high molar
absorbance of 4-nitroaniline it may be used in a
continuous assay, which makes it suitable for auto-
matic analysers. Alanyl-ß-naphthylamide is more con-
venient for histochemical analysis and for enzyme
detection on electrophoretograms, because the prod-
uct diffuses only slowly and the diazo-coupled prod-
uct precipitates; this makes long incubation times
possible (92, 106, 107).
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Other substrates which have been proposed for alan-
ine aminopeptidase determination are leucyl-3-carb-
oxy-4-hydroxyanilide in an endpoint method (108),
and fluorogenic substrates (109, 110).
Cystyl aminopeptidase
Several synthetic substrates have been employed in
the analysis of serum cystyl aminopeptidase; these are
generally di-substituted derivates of cystine, e. g. cys-
tyl-di-ß-naphthylamide, S-benzyl-cysteyl-ß-naphthyl-
amide, cystyl-bis-4-nitroanilide and S-benzyl-cysteyl-
4-nitroanilide (93, 111-114). The relative activity
towards these different substrates, the pH optimum
and the influence of effectors depend on the tissue
source, which indicates lack of substrate specificities
(61, 62). Uete et al. (62) concluded that S-benzyl-
cysteyl-4-nitroanilide was the most specific of four
cystyl aminopeptidase substrates tested. S-benzyl-cys-
teyl-4-nitroanilide has effectively gained preference
(115), because of its relatively good solubility, the fact
that among these cystine substrates it is hydrolysed
the most rapidly by cystyl aminopeptidase and that
it is easy to use in an automated assay (116 — 118).
Mizutani et al. (119) measured cystyl aminopeptidase
activity in serum with leucyl-ß-naphthylamide as sub-
strate. The hydrolysis of the same substrate by alanine
aminopeptidase was inhibited by methionine. The ac-
tivity measured in this way was found to correlate
well with hydrolysis of cystyl-di-ß-naphthylamide. A
fluorimetric method with S-benzyl-cys-methylcou-
marin was proposed by Suzuki et al. (120).
Glycation
Alanine aminopeptidases from various tissues differ
in electrophoretic mobility, heat sensitivity and sus-
ceptibility to lectin precipitation (23, 24, 42, 96, 124,
125). Treatment with neuraminidase abolishes the dif-
ferences in electrophoretic mobility of the anodic
bands of alanine aminopeptidase from various tissues
(24). Böhme et al. (44) compared the carbohydrate
groups of alanine aminopeptidases from liver, kidney
and pancreas. They found the liver enzyme to contain
the highest number of sialic acid groups, and further
that sialic acid contents correlate well with molecular
charges. These therefore appear to be the main cause
of intertissular variation of alanine aminopeptidase
on electrophoresis gels.
Böhme et al. (44) also found a variation in the number
of glucose groups. Lorentz (125) found that differ-
ences in precipitation of alanine aminopeptidase from
different tissues by various lectins persist after neur-
aminidase treatment, which also indicates variations
in sugar groups other than sialic acids.
/w/ratissular variations in molecular charge have been
found for the pancreas enzyme and the kidney enzyme
(14, 44). Recently it was shown that normal human
serum contains two isoforms of alanine aminopepti-
dase, which differ in sialic acid content (40).
Alanine aminopeptidases from cancerous tissues dif-
fer from alanine aminopeptidases from the corre-
sponding normal tissues in electrophoretic mobility
and behaviour on ion-exchange media (9, 26, 126,
127). These differences are also attributed to varia-
tions in sialic acid content, and no immunological
differences have been established (9, 122).
Multiple Forms of Alanine Aminopeptidase
Among the various aminopeptidases, the heteroge-
neity of alanine aminopeptidase has been most widely
studied. Electrophoretic, Chromatographie and im-
munological techniques have been used for this pur-
pose. A first review on this subject was published in
1970 by Boivin et al. (23).
Several groups have compared alanine aminopepti-
dase from different human tissues by immunological
techniques, but no differences in antigenicity have
been found (121 -123). It thus appears that all alanine
aminopeptidase isoforms originate from a single gene
product and that the heterogeneity is due to post-
translational modifications. Three mechanisms caus-
ing the heterogeneity have been identified: glycation,
limited proteolysis and aggregation with other mole-
cules.
Multimolecular complexes
Liver alanine aminopeptidase in its native form is an
amphiphilic protein, anchored to the outer side of
canalicular plasma membranes (22, 127, 128, 129).
Enzymes with a similar localization are -glutamyl-
transferase (EC 2.3.2.2) and alkaline phosphatase (EC
3.1.3.1). For all these enzymes slower- or non-mi-
grating bands may be detected upon polyacrylamide
or agarose gel electrophoresis of sera from patients
with liver disease (83, 106, 107, 124, 130-132). Sim-
ilarly, enzyme forms of large size may be found in
these sera by gel filtrations (133 — 135).
In 1972, Shinkai & Akedo (134) noticed a resemblance
in the composition of the high molecular-mass forms
and the liver plasma membrane, and they concluded
that the large forms represented multienzyme com-
plexes derived from the liver plasma membrane. De
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Broe et al. (136) isolated vesicles from sera of patients
with cholestasis, which contained the membranous
enzymes alanine aminopeptidase, alkaline phospha-
tase, γ-glutamyltransferase and 5'-nucleotidase, but
no cytosolic enzymes. The vesicles were thought to be
plasma membrane fragments. They subsequently es-
tablished that the 'shedding" of plasma membrane
fragments into the surrounding medium is a common
phenomenon in living cells (137). The plasma mem-
brane fragments in human serum appear to be derived
from liver cells and not to be of biliary origin (129).
Similar fragments in urine originate from the brush
border membrane of the kidney proximal tubuli (138,
139).
Amphiphilic forms of alanine aminopeptidase, alka-
line phosphatase and γ-glutamyltransferase may be
obtained in vitro by incubation of plasma membranes
with detergents or bile salts (45, 140-143). The en-
zymes appear in a high molecular mass form, which
is due to an attachment of the hydrophobic domain
to other molecules (143, 144). Since amphiphilic, ag-
gregated forms of alanine aminopeptidase, alkaline
phosphatase and γ-glutamyltransferase are also pres-
ent in sera from patients with cholestasis, it has been
supposed that these forms may be solubilized in vivo
by the action of bile salts on the liver plasma mem-
brane (145, 146). Incubation of serum or urine with
Triton X-100 dissociates the aggregates; complexes of
enzymes with detergent molecules which bind to the
hydrophobic domain are obtained (107, 147—149).
The composition of the multimolecular complexes of
alanine aminopeptidase, γ-glutamyltransferase and al-
kaline phosphatase has been analysed by electropho-
resis, gel filtration and precipitation techniques. Crof-
ton & Smith (131) found the three enzymes to be
associated with lipoprotein X. Aggregated forms of
alanine aminopeptidase of intermediate relative mo-
lecular mass (400-600000) and high MT
(< 1 000 000) were found by Wenham et al. (135) upon
gel filtration of cholestatic sera. Sanderink et al. (40)
found several groups of multimolecular forms by the
use of micro-two-dimensional electrophoresis (fig. 1).
Some alanine aminopeptidase forms of intermediate
Μτ may be precipitated by antibodies against apoli-
poprotein A or by polyanions, which indicates the
existence of high density lipoprotein (HDL-) alanine
aminopeptidase complexes (135, 150). Complexes of
γ-glutamyltransferase and HDL have also been dem-
onstrated (135, 151, 153), but not of alkaline phos-
phatase and HDL (135).
Alanine aminopeptidase, alkaline phosphatase and γ-
glutamyltransferase may also be associated with apo-
lipoprotein Β or low density lipoproteins (131, 150,
152, 154).
While the composition of the multimolecular com-
plexes is becoming better understood, their origin
remains partly abscure. Wenham et al. (135, 144)
observed that amphiphilic enzyme forms, which were
solubilized from liver tissue by bile salts, reaggregated
when the bile salt concentration was lowered. More-
over, they were not able to extract intermediate mo-
lecular mass complexes of γ-glutamyltransferase from
liver tissue in vitro, unless in the presence of serum
(143). These results would indicate that the multi-
molecular complexes may be formed by reaggregation
of amphiphilic proteins in serum.
On the other hand, one would expect such a mecha-
nism to result in a random distribution of the various
complexes. However, the micro-2-dimensional elec-
trophoresis patterns of the three enzymes (alanine
aminopeptidase, alkaline phosphatase, γ-glutamyl-
transferase) from similar sera are clearly different
(150) and so are the elution profiles of the three
enzymes on a gel filtration column and the net charges
of the complexes (135,148). Differences in lipoprotein
composition have also been established by immuno-
precipitation studies. These results would be more
consistent with a specific composition of the enzyme-
lipoprotein complexes, reflecting their origin. At this
moment neither of the two possibilities can be com-
pletely excluded.
Complexes of numerous serum enzymes with immu-
noglobulins have been detected. The specificity of the
enzyme-immunoglobulin bond has been established
in some cases. Complexes of alanine aminopeptidase
with IgA and light (λ-) chains were found by Sudo &
Kanno (155). The same group observed an alanine
aminopeptidase-IgG(K) complex in the serum of a
patient with rheumatoid arthritis, together with com-
plexes of immunoglobulins with other enzymes (156).
Limited proteolysis
Autolysis of liver tissue or incubation of membrane
fractions with proteolytic enzymes such as papain,
trypsin and bromelain result in the solubilization of
alanine aminopeptidase (21, 22, 25, 45, 140). The
hydrophobic, anchoring part of the enzyme is cleaved
off, so that the solubilized enzyme has a hydrophilic
character (45). Although most studies on this subject
have been performed on animal tissues, the model
also seems to be true for human alanine aminopep-
tidase.
The amphiphilic, aggregated form of alanine amino-
peptidase in serum can be dissociated from the mul-
timolecular complexes by incubation with proteolytic
enzymes in the same way that it is separated from
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membranes. This also results in the appearance of
low molecular mass, hydrophilic forms (40, 107, 131,
144).
Alanine aminopeptidases in normal serum have also
a hydrophilic character. These forms are thought to
be derived from the liver. In liver disease, alcohol
consumption or drug intake, additional hydrophilic
forms, named F-alanine aminopeptidases because of
their fast mobility in polyacrylamide gel electropho-
resis, may be detected in serum (40, 41). These forms
have a slightly lower molecular mass than the normal
alanine aminopeptidases (fig. 1). Similar forms may
be obtained by incubation of normal serum alanine
aminopeptidases or multimolecular complexes with
papain. These additional forms are thus probably
cleaved at a site different from that under normal
conditions. The cause of this different proteolysis has
not been elucidated, but it may be related to the
induction of membrane proteases or perturbances of
the liver plasma membranes (40, 41).
Isoelectric focusing *-^ > 0
N
l e rn
Fig. 1. Micro-two-dimensional electrophoresis gel of serum
stained for alanine aminopeptidase (ΑΑΡ). Ν: normal
forms. F: F (fast)-AAR 1 -5*. multimolecular complexes
(with modifications from 1. c. (40)).
Multiple forms of other aminopeptidases
As in the case of alanine aminopeptidase, no evidence
of genetic polymorphism has been reported for leucine
aminopeptidase or cystyl aminopeptidase.
Two forms of leucine aminopeptidase were observed
by Lederne et al. (10) in human liver which could be
separated by DEAE-Sephacel chromatography. A
leucine aminopeptidase isoform has been observed by
Maekawa et al. (156) in the serum of a patient with
rheumatoid arthritis. This isofonn was a leucine ami-
nopeptidase-IgG complex.
As mentioned above, a heterogeneity observed for
cystyl aminopeptidase may often be' related to a lack
of specificity of substrates. However, two isoforms of
cystyl aminopeptidase were demonstrated by Page et
al. (157) in pregnancy sera, which appear to have
similar substrate specificities (156, 158). Sj holm &
Yman (159) found that the two forms were of the
same size. The two serum cystyl aminopeptidases elute
together on gel filtration (39). These findings are in
agreement with those of Sanderink et al. (40) who
showed that the two forms have an identical molec-
ular mass on 2-dimensional electrophoresis gels, but
differ in isoelectric point.
Clinical Significance of Aminopeptidases in Serum
Alanine aminopeptidase
Evaluations of the clinical value of the analysis of
alanine aminopeptidase in serum were mainly carried
out in the early sixties, after initial reports of Goldbarg
& Rutenburg (91, 160) that (what now may be iden^
tified as) alanine aminopeptidase was a specific
marker for carcinoma of the head of the pancreas.
Subsequently they also found elevated alanine ami-
nopeptidase activities in cases of biliary and hepatic
tumours, intra- and extrahepatic obstruction and
drug-induced hepatitis (161). Others found that serum
alanine aminopeptidase was elevated in cases of pan-
creas carcinoma only when accompanied by biliary
obstruction (162,163). It appears that increased alan-
ine aminopeptidase concentrations are generally
found in cases of intra- and extrahepatic cholestasis,
malignant hepatobiliary disease and alcoholic liver
disease (23, 164-166). γ-Olutamyltransferase, which
is more sensitive, and also alkaline phosphatase are
now often preferred for purposes of diagnostic screen-
ing for hepatobiliary disease.
Although alanine aminopeptidase elevations are
rather specific for cases in which obstruction occurs
— possibly because it is specifically localized in can-
alicular membranes (27, 129) - the value of a single
alanine aminopeptidase measurement in the differ-
ential diagnosis of liver disease is poor. Yet, .both Neef
et al. (167) and Crofton et al. (168) found by the use
of multivariant analysis that alanine aminopeptidase
was a useful discriminator when associated with other
parameters. In this matter alanine aminopeptidase is
more efficient than γ-glutamyltransferase, the eleva-
tions of which in serum are rather; unspecific.
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There are few recent data on the biological variations
of alanine aminopeptidase in serum. Alanine amino-
peptidase activities increase in childhood and decrease
after puberty (101). Alanine aminopeptidase activities
are higher in men than in women (100, 101, 105).
Activity in serum may be increased by smoking, al-
cohol consumption or drug intake. Hence, it appears
possible that serum alanine aminopeptidase is influ-
enced by microsomal enzyme induction in the liver,
similarly to γ-glutamyltransferase (101, 169).
Alanine aminopeptidase isoforms
Interest in the determination of alanine aminopepti-
dase isoforms in serum arose partly because of a
report by Beier et al. (170). They separated two alan-
ine aminopeptidase bands from serum by agar gel
electrophoresis and stated that the intensity of one
band correlated with cholestasis, while the other one
was a sensitive and specific marker for pancreatic
disease. However, Schlaeger & Kattermann (171)
found 40% of false negative results in cases of pan-
creatic disease. The appearance of a second alanine
aminopeptidase band was related to the presence of
cholestasis. Several other groups using agar gels or
polyacrylamide gels as support media obtained similar
results; additional slower moving alanine aminopep-
tidase bands are generally found when cholestasis is
present or may be suspected (23, 106, 124, 130).
Early studies also showed slower moving alanine ami-
nopeptidase bands in sera of subjects taking oral
contraceptive drugs or anticonvulsant drugs (172,
173). No indication was found whether this was due
to liver damage or enzyme induction. Phillips & Man-
ildi (174) found additional alanine aminopeptidase
bands on cellulose-acetate membranes in cases of met-
astatic disease, sometimes without signs of liver in-
volvement.
Most authors have concluded that the fact that ad-
ditional bands appear is of no value for a differential
diagnosis of hepatobiliary diseases. The large number
of additional alanine aminopeptidase bands in hepa-
tobiliary disease, the lack of their characterization in
early studies and the range in analytical methods has
rendered interpretations and comparisons of alanine
aminopeptidase patterns impossible. But now that the
multiple forms have become better characterized —
and thus easier to identify — it is possible that specific
subtractions of alanine aminopeptidase and other
liver enzymes may become of diagnostic interest. For
example,, Wenham et al. (132) reported recently that
some HDL-y-glutamyltransferase complexes are pre-
dominant in patients with extrahepatic jaundice. San-
derink et al. (41) found that the F (fast) form of
hydrophilic alanine aminopeptidase separated on
polyacrylamide electrophoresis gels may be a sensitive
marker of alcohol abuse.
However, the development of more quantitative meth-
ods of analysis of these isoforms appears necessary in
order to perform a definitive evaluation of their clin-
ical interest and to initiate a still hypothetical large
scale application in routine laboratory medicine.
Leucine aminopeptidase
Leucine aminopeptidase is a liver cytosolic enzyme,
and therefore a marker for hepatic cell lysis (8). Some
authors have even stated that leucine aminopeptidase
is a more sensitive marker for acute hepatitis than the
aminotransferases (81, 175). Kanno et al. (84) com-
pared leucine aminopeptidase values for different
groups of patients with hepatic diseases. The highest
activities of leucine aminopeptidase in serum were
found for patients with acute hepatitis with different
causes or with embolized hepatoma. Relatively high
increases were found in sera from patients with pro-
longed or chronic hepatitis, cirrhosis, or non-embol-
ized hepatoma. Only slight elevations were noticed in
cases of obstructive disease or microsomal enzyme
induction. Pancheva-Haschen & Haschen (175) ob-
served relatively elevated leucine aminopeptidase val-
ues as compared to transaminase levels in patients
with active cytomegalovirus infections. They subse-
quently found that leucine aminopeptidase, alanine
aminopeptidase and γ-glutamyltransferase activities
were higher in lymphoid cells than in normal lym-
phocytes. It was concluded that serum leucine ami-
nopeptidase may be a marker for plasmacytoid lym-
phocyte proliferation in acute viral infections.
Cystyl aminopeptidase
Serum cystyl aminopeptidase levels increase during
normal pregnancy until shortly before the onset of
labour (119, 176,177). Cystyl aminopeptidase activity
in amniotic fluid shows a decrease during pregnancy
(53). Whether a shift in the oxytocin/cystyl amino-
peptidase ratio induces the onset of labour remains
hypothetical (57, 119).
The fact that cystyl aminopeptidase is produced by
the placenta has led to studies on its utility as a
placental function test. Effectively, serum cystyl ami-
nopeptidase levels are statistically significantly lower
in chronic placental insufficiency or before a prema-
ture birth (166, 178, 179). However, other placental
function tests, i. e. human placental lactogen and oes-
triol are preferred for this purpose (180). Moreover,
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the interest of placental function tests as a whole has
been questioned recently, because of too high a level
of false positive and false negative results (180).
Cystyl aminopeptidase also has angiotensinase activ-
ity and relatively high levels of the enzyme have been
found in pregnancy sera in cases of pre-eclampsia and
low levels in the late stage of severe pre-eclampsia
(181). Serum activities of aspartyl aminopeptidase
(aminopeptidase A), which also exhibits angiotensi-
nase activity, show a significant decrease in cases of
pre-eclampsia (182). Cystyl aminopeptidase levels
have also been reported to be increased in sera of
women with ovarian adenocarcinomas, but this has
not been confirmed (183, 184).
Tripeptide aminopeptidase
The clinical usefulness of tripeptide aminopeptidase
has been investigated only very recently by Kanda et
al. (66, 185). Because tripeptide aminopeptidase is
mainly localized' in the cytosolic subfraction of the
liver, the activity in sera of patients with liver disease
correlates well with those of alanine aminotransferase.
An exception to this is found in hepatoma, in which
tripeptide aminopeptidase shows a relatively greater
increase. This was explained by a changed tripeptide
aminopeptidase/alanine aminotransferase ratio in
cancerous tissues (85). Further, preliminary results
showed an increase of tripeptide aminopeptidase in
some patients with leukaemias or autoimmune dis-
eases, possibly related to the high tripeptide amino-
peptidase activities that are present in leukocytes.
Conclusion
Studies on the biological functions of amiriopepti-
dases and on the value of their determination in
clinical chemistry have been complicated by the het-
erogeneity of these enzymes, with overlapping speci-
ficities for both biological and synthetic substrates,
and by the lack of characterization of the individual
enzymes. Further data are also required on their mul-
tiple forms, especially for alanine aminopeptidase.
Aminopeptidases have now been purified from var-
ious tissues and characterized, and this work is still
in progress. Circulating multiple forms have also been
better characterized, but their origin is still unclear.
These developments should lead to more specific,
quantitative assays, which may increase our under-
standing of the biological roles of aminopeptidases,
provide an aid to the study of pathological processes
and give a better insight iii their significance in clinical
chemistry.
References
1. Linderstr0m-Langs K. (1929) Hoppe-Seyler's Z. Physiol.
Chem. 182, 151-174.
2. Delange, R. J. & Smith, E. L. (1971) In: The Enzymes,
Vol. III. (Boyer, P. D., ed.) pp. 81-118, Academic Press,
New York.
3. Kohno, H., Kanda, S. & Kanno, T. (1986) J. Biol. Chem.
2(57, 10744-10748.
4. Hanson, H. & Frohne, M. (1976) In: Methods in Enzy-
mology, Vol. XLV (Colowick, S. P. & Kaplan, N. O., eds.)
pp. 504-521, Academic Press, New York.
5. Thompson, G. A. & Carpenter, F. H. (1976) J. Biol. Chem.
257, 1618-1624.
6. Taylor, H., Volz, K. W., Lipscomb, W. N. & Takemoto,
L. J. (1984) J. Biol. Chem. 259, 14757-14761.
7. Vincent-Piquet, O., Rogez, J. L. & Plaquet, R. (1984)
Biochimie 66, 171-174.
8. Niinobe, M. & Fujii, S. (1980) J. Biochem. Tokyo 87,
195-203.
9. Niinobe, M., Tamura, Y, Arima, T. & Fujii, S. (1979)
Cancer Res. 39, 4212-4217.
10. Lederne, N., Vincent-Piquet, O., Hennon, G. & Plaquet,
R. (1983) Biochimie 65, 397-404.
11. Kao, Y. J., Starnes, W. L. & Behal, F. J. (1978) Biochem-
istry 77, 2990-2994.
12. Freitas, J. O. Jr., Guimaras, J. A., Borges, D. R. & Prado,
J. L. (1979) Int. J. Biochem. 70, 81-89.
13. McClellan, Jr., J. B., Garner, C. W. (1980) Biochim. Bio-
phys. Acta 673, 160-167.
14. Sidorowicz, W., Jackson, G. C. & Behal, F. J. (1980) Clin.
Chim. Acta 104, 169-179.
15. Lalu, K., Lampelo, S. & Vanha-Perttula, f. (1986)
Biochim. Biophys. Acta 873, 190-197.
16. Little, G. H. & Behal, F. J. (1971) Proc. Soc. Exp. Biol.
Med. 736, 954-957.
17. Sidorowicz, W., Zownir, O. & Behal, F. J. (1981) Clin.
Chim. Acta 777, 69-79.
18. Hersh, L. B. (1985) J. Neurochem. 44, 1427-1435.
19. Giros, B., Gros, C., Solhonne, B. & Schwartz, J. L. (1986)
Moi. Pharmacol. 29, 281-287.
20. Bausback, H. H. & Ward, P. E. (1986) Biochim. Biophys.
Acta 882, 437-444.
21. Behal, F. J,, Asserson, B., Dawson, F. & Hardman, J.
(1965) Arch. Biochem. Biophys. 777, 335-344.
22. Emmelot, P., Visser, A. & Benedetti, E. L. (1968) Biochim.
Biophys. Acta 150, 364-375.
23. Boivin, P., Fauvert, R., Hakim, J., Dastugue, B. & troube,
H. (1970) Pathol. Biol. 18, 287-294.
24. Lorentz, K., Marunowski, A. & Ritter, U. (1974) J. Clin.
Chem. Clin. Biochem. 72, 468-473.
25. Scherberich, J. E., Falkenberg, F. W., Mondorf, A. W.,
Muller, H. & Pfleiderer, G. (1974) Clin. Chim. Aeta 55,
179-197.
26. Tamara, Y., Niinobe, M., Arima, T., Okuda, H. & Fujii,
S. (1975) Cancer Res. 35, 1030 -1034.
27. Roman, L. M. & Hubbard, A. L. (1983) J. Cell. Biol. 96,
1548-1558.
28. Starnes, W. L. & Behal, F. J. (1974) Biochemistry 73,
3221-3227.
29. Behal, F. J., Little, G. H. & Klein, R. A. (1969) Biochim.
Biophys. Acta 178, 118 -127. · f
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 12
Sanderink et al.: Aminopeptidases, a review 805
30. Little, G. H. & Behal, F. J. (1971) Biochim. Biophys. Acta
243, 312-319.
31. Hiwada, K., Ito, T., Yokoyama, M. & Kokubu, T. (1980)
Eur. J. Biochem. 104, 155-165.
32. Behal, F. J. & Story, M. N. (1969) Arch. Biochem. Bio-
phys. 737, 74-82.
33. Hiwada, K. & Kokubu, T. (1977) Clin. Chim. Acta 80,
395-401.
34. Hiwada, K., Yokoyama, M. & Kokubu, T. (1981) Biomed.
Res. 2, 517-526.
35. Rehfeld, N., Peters, J. E., Giesecke, H. & Haschen, R. J.
(1967) Acta Biol. Med. Genn. 19, 819-830.
36. Kurauchi, O., Mizutani, S., Okano, K., Narita, O. &
Tomoda, Y. (1986) Enzyme 35, 197-205.
37. Tokioka-Terao, M., Hiwada, K. & Kokubu, T. (1984)
Enzyme 32, 65-75.
38. Lalu, K., Lampelo, S. & Vanha-Perttula, T. (1985) Int. J.
Biochem. 77, 1227-1235.
39. Oya, M., Yoshino, M. & Mizutani, S. (1975) Experientia
37, 1019-1020.
40. Sanderink, G. J. C. M., Artur, Y, Galteau, M. M., Well-
man-Bednawska, M. & Siest, G. (1986) Electrophoresis 7,
471-475.
41. Sanderink, G. J., Artur, Y, Faille, F. & Siest, G. (1988)
Clin. Chim. Acta, in press.
42. Hiwada, K,, Terao, M., Nishimura, K. & Kokubu, T.
(1977) Clin. Chim. Acta 76, 267-275.
43. Garner, C. W. & Behal, F. J. (1974) Biochemistry 13,
3227-3233.
44. Böhme, L, Hütter, H. J., Gerlach, W. & Haschen, R. J.
(1976) Enzyme 27, 464-470.
45. Maroux, S. & Louvard, D. (1976) Biochim, Biophys. Acta
419, 189-195.
46. Noren, O. & Sjöström, H. (1980) Eur. J. Biochem. 104,
25-31.
47. Mattenheimer, H., Frölke, W., Grötsch, H. & Simane, Z.
(1986) Clin. Chim. Acta 160, 129-135.
48. Schlaeger, R. (1973) J. Clin. Chem. Clin. Biochem. 77,
326-328.
49. Lorentz, K., Koch, C.-D., Flatter, B. & Molz, J. (1975) J.
Clin. Chem. Clin. Biochem. 13, 49 — 52.
50. Nakagawa, S. & Tsuji, H. (1966) Clin. Chim. Acta 13,
155-160.
51. Von Fekete, K. (1930) Endokrinologie 7, 364-369.
52. Kleiner, H. & Brouet-Yager, M. (1973) Clin. Chim. Acta
45, 109-112.
53. Roy, A. C., Kottegoda, S. R., Viegas, O. A. C. & Ratnam,
S. S. (1986) Obstet. Gynecol. 68, 614-617.
54. Oya, M., Wakabayashi, T., Yoshino, M. & Mizutani, S.
(1976) Physiol. Chem. Phys. 8, 327-335.
55. Lalu, K., Lampelo, S. & Vanha-Perttula, T. (1983) In:
Progress in Clinical Enzymology, 2. (Goldberg, D. M. &
Werner, M. eds.) pp. 299-309, Masson, New York.
56. Mizutani, S., Yoshino, M. & Oya, M. (1976) Clin.
Biochem. 9, 228.
57. Oya, M., Yoshino, M. & Asano, M. (1974) Experientia
30, 985-986.
58. Kleiner, H., Dictus^Vermeulen, C., May-Cocriamont, C.,
Brouet-Yagef, M., Popowski, A.', Mosselmans, R., Graff,
G. (1980) Clin, Chim. Acta 101, 113-123.
59. Lampelo, S., Lalu, K. & Vanha-Perttula, T. (1983) Int. J.
Biochem. 75, 709-714.
60. Unger, T. & Struck, H. (1980) J. Clin. Chem. Clin.
Biochem. 18, 631-635.
61. Tiderström, G. &. Heinegard, D. (1978) Clin. Chim. Acta
55,293-304.
62. Uete, T., Motokura, H., Kitano, Y, Fukutani, C., Uenishi,
N. & Ando, N. (1981) J. Clin. Chem. Clin. Biochem. 19,
145-151.
63. Mizutani, S., Okano, K., Hasegawa, E., Sakura, H. &
Yamada, M. (1981) Biochim. Biophys. Acta 678, 168-
170.
64. Brouet-Yager, M., Kleiner, H., Van Bogaert, E. & Graff,
G. L. A. (1974) Clin. Chim. Acta 54, 387-389.
65. Rankin, B. B., Mclntyre, T. M. & Curthoys, N. P. (1980)
Biochem. Biophys. Res. Comm. 96, 991—996.
66. Kanda, S., Maekawa, M., Kohno, H., Sudo, K., Hishiki,
S., Nakamura, S. & Kanno, T. (1984) Clin. Biochem. 77,
253-257.
' 67. Hayashi, M. & Oshima, K. (1980) J. Biochem. 87,1403-
1411.
68. Kanda, S., Sudo, K. & Kanno, T. (1984) Clin. Chem. 30,
843-846.
69. Glenner, G. G., McMillan, P. J. & Folk, J. E. (1962)
Nature 194, 867.
70. Lalu, K., Lampelo, S., Nummelin-Kortelainen, M. &
Vanha-Perttula, T. (1984) Biochim. Biophys. Acta 759,
324-333.
71. Agrawal, Y. & Vanha-Perttula, T. (1985) Int. J. Androl.
5,243-256.
72. Fleminger, G. & Yaron, A. (1983) Biochim. Biophys. Acta
743, 437-446.
73. Holtzman, E. J., Pillay, G., Rosenthal, T. & Yaron, A.
(1987) Anal. Biochem. 752, 476-484.
74. Sidorowicz, W., Szechinski, J., Canizaro, P. C. & Behal,
F. J. (1984) Proc. Soc. Exp. Biol. Med. 775, 503-509.
75. Appel, W. (1983) J. Clin. Chem. Clin. Biochem. 27,
53-61.
76. Mantle, D., Lauffart, B., McDermott, J. R., Kidd, A. M.
& Pennington, R. J. T. (1985) Eur. J. Biochem. 747, 307-
312.
77. Suda, H., Aoyagi, T., Takeuchi, T. & Umezawa, H. (1976)
Arch. Biochem. Biophys. 777, 193—200.
78. Patterson, E. K., Hsiao, S. H. & Keppel, A. (1963) J. Biol.
Chem. 235, 3611-3620.
79. Hafkenscheid, J. C. M. (1984) In: Methods of enzymatic
analysis, 3rd edn. vol. 5 (Bergmeyer, H. U., ed.) pp. 2 — 15,
Verlag Chemie Publ., Weinheim.
80. Appel, W. (1974) In: Methods of enzymatic analysis, 2rd
edn. vol. 2 (Bergmeyer, H. U., ed.) pp. 949-999, Verlag
Chemie Publ., Weinheim.
81. Plaquet, R., Lederne, N., Vincent-Piquet, O. & Biserte,
G. (1973) Clin. Chim. Acta 46, 91-103.
82. Tamura, Y., Niinobe, M., Arima, T., Okuda, H. & Fujii,
S. (1973) Biochim. Biophys. Acta 327, 437-445.
83. Hafkenscheid, J. C. M. & Kohler, B. E. M. (1985) J. Clin.
Chem. Clin. Biochem. 23, 393-398.
84. Kanno, T., Maekawa, M., Kanda, S., Kohno, H. & Sudo,
K. (1984) Am. J. Clin. Pathol. 52, 700-705.
85. Takamiya, S., Ohshima, T., Tanizawa, K. & Soda, K.
(1983) Anal. Biochem. 730, 266-270.
86. Haschen, R. J., Farr, W. & Reichelt, D. (1968) J. Clin.
Chem. Clin. Biochem. 6, 11-18.
87. Fleisher, G. A., Pankow, M. & Warmka, C. (1964) Clin.
Chim. Acta 9, 259-268.
88. Kusakabi, H., Midorikawa, Y. & Fujishima, T. (1984)
Agric. Biol. Chem. 48, 1357-1358.
89. Fleisher, G. A., Pankow, M. & Warmka, C. (1964) Clin.
Chim. Acta 9, 254-258.
90. Hwang, S. Y, Kingsbury, W. D., Hall, N. M., Jakas, D.
R., Dünn, G. L. & Gilvarg, L. (1986) Anal. Biochem. 154,
552-558.
91. Goldbarg, J. A. & Rutenburg, A. M. (1958) Cancer 77,
283-291.
92. Goldbarg, J. A, Pineda, E. P. & Rutenberg, A. M. (1959)
Am. J. Clin. Pathol. 32, 571-575.
93. Tuppy, H., Wiesbauer, U. & Wintersberger, E. (1962)
Hoppe Seyler's Z. Physiol. Chem. 32P, 278-288.
94. Behal, F. J., Hamilton, R. D., Kanavage, C. B. & Kelly,
C. (1963) Arch. Biochem. Biophys. 100, 308-312.
95. Farr, W., Rehfeld, N., Reichelt, D. & Haschen, R. J. (1968)
Z. Med. Labortechn. 9, 78-86.
96. Rehfeld, N., Peters, J. E., Giesecke, H., Bcicr, L. &
Haschen, R. J. (1967) Acta Biol. Med. Germ. 19, 809-
818.
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 12



































Nagel, W., Willig, F. & Schmidt, F. H. (1964) Klin. Woch- 131.
enschr. 42, 447-449.
Recommendations of the German Society for Clinical 132.
Chemistry (1972) J. Clin. Chem. Clin. Biochem. 10, 182-
192. 133·
Hafkenscheid, J. C. M. & Dijt, C. C. M. (1980) Tijdschrift
N.V.K.C. 5, 17-19. 134.
Tokioka-Terao, M., Hiwada, K. & Kokubu, T. (1985)
Enzyme 33, 181-187. 135.
Sanderink, G. J., Artur, Y., Schiele, F., Gueguen, R. &
Siest, G. (1988) Clin. Chem. 34, 1422-1426. 136.
Jung, K. & Scholz, D. (1980) Clin. Chem. 26,1251-1254.
Evans, J. O. (1985) Clin. Chem. 57, 652. 137.
Redondo, F. L., Pascual, T., Bergon, E. & Miravalles, E.
(1986) Clin. Chem. 52, 912-913. 138.
Mueller, P. W., Phillips, D. L. & Steinberg, K. K. (1987)
Clin. Chem. 33, 363-366. 139.
Peters, J. E., Nilius, R. & Otto, L. (1973) Clin. Chim.
Acta 45, 177-187. 140.
Sanderink, G. J., Artur, Y., Wellman-Bednawska, M. &
Siest, G. (1986) In: Recent progress in two-dimensional 141.
electrophoresis (Galteau, M. M. & Siest, G., eds.) pp. 142.
193 — 196, Presses Universitaires de Nancy Publ., Nancy.
Shimamoto, M., Takewaki, S., Sakuraoka, S., Nagasawa, 143.
T., Kuroivva, K., Kodama, O. & Akatsuka, T. (1985) Clin.
Chem. 31, 1636-1639. 144.
Carmel, A., Kessler, E. & Yaron, A. (1977) Eur. J.
Biochem. 73, 617-625. 145.
Saifuku. K., Sekine, T., Namihisu, T., Takahashi, T. &
Kanaoka, Y. (1978) Clin. Chim. Acta 84, 85-91. 146.
Tuppy, H. & Nesvadba, H. (1957) Monatsch. Chem. 88,
977-988.
Wintersberger, E., Muller-Hartburg, W. & Tuppy, H.
(1966) Clin. Chira. Acta 14, 786-792.
Van Oudheusden, A. P. M. (1972) J. Clin. Chem. Clin. 147.
Biochem. W, 345-346.
Tovey, J. E., Dawson, P. J. G. & Fellowes, K. P. (1973) 148.
Clin. Chem. 19, 756-761.
Van Oudheusden, A. P. M. (1984) In: Methods of enzy- 149.
matic analysis, 3rd edn. vol. 5 (Bergmeyer, H. U., ed.) pp.
15-20, Verlag Chemie Publ., Weinheim. 150.
Chapman, L., Burrows-Peakin, R., Rege, V. P. & Silk, E.
(1974) Clin. Chim. Acta 51, 335-339. 151.
Van Buul, T. & Van Oudheusden, A. P. M. (1974) Clin.
Chim. Acta 54, 263-268. 152.
Perrault, C., Peynet, J., Legrand, Α., Paolaggi, F. & Rous-
selet, F. (1983) Ann. Biol. Clin. 41, 273-276. 153.
Mizutani, S., Hayakawa, H., Akiyama, H., Sakura, H., 154.
Yoshino, M., Oya, M. & Kawashima, Y. (1982) Clin.
Biochem. 75, 141-145. 155.
Suzuki, M., Takashi, U., Takahashi, T, Kanaoka, Y.,
Okuyama, T., Furuya, H. & Sekine, T. (1981) Clin. Chim. 156.
Acta 7/5,223-228.
Peters, J. E., Rehfeld, N., Beier, L. & Haschen, R. J. 157.
(1968) Clin. Chim. Acta 19, 277-286.
Ito, T, Hiwada, K. & Kokubu, T. (1980) Clin. Chim. Acta 158.
707, 139-143.
Sidorowicz, W, Hsia, W.-C., Maslej-Zownir, O. & Behal, 159.
F. J. (1980) Clin. Chim. Acia 707, 245-256.
Dingjan, P. G., Jongeneel, J., Postma, T. & Stroes, J. A. 160.
P. (1973) Clin. Chim. Acta 49, 215-224.
Lorentz, K. (1981) J. Clin. Chem. Clin. .Biochem. 19, 161.
1181-1187.
Hiwada, K., Terao, M. & Kokubu, T. (1977) Clin. Chim. 162.
Acta 79, 569-573.
Hiwada, K., Terao, M., Ono, M. & Kokubu, T. (1978) 163
Clin. Chim. Acta 83, 185-188.
Emmelot, P. & Visser, A. (1971) Biochim. Biophys. Acta 164
241, 273-289.
 i65\
De Broe, M. E., Roels, F, Nouwen, E. J., Claes, L. &
Wieme, R. J. (1985) Hepatology 5, 118-128.
Bornschein, W. (1975) Clin. Chim. Acta 61, 325-333. 16*6
Crofton, P. M. & Smith, A. F. (1981) Clin. Chem. 27,
867-874.
Wenham, P. R., Horn, D. B. & Smith, A. F. (1985) Clin.
Chem. 31, 569-573.
Dunne, J., Fenelly, J. J. & McGeeney, K. (1967) Cancer
20,71-76.
Shinkai, K. & Akedo, H. (1972) Cancer Res. 32, 2307-
2312. · ι
Wenham, P. R., Horn, D. B. & Smith, A. F. (1984) Clin.
Chim. Acta 141, 205-218.
De Broe, M. E., Borgers, M. & Wieme, R. J. (1975) Clin.
Chim. ActaJP, 369-372.
De Broe, M. E., Wieme, R. J., Logghe, G. N. & Roels,
F. (1977) Clin. Chim. Acta 81, 237-245.
Linder, M. & Sudaka, P. (1982) Clin. Chim. Acta 118,
ηη £5
Jung, K. & Pergande, M. (1983) Clin. Chem. 29, 392-
393.
Wacker, H., Lehky, P., Vanderhaeghe, E & Stein, E. A.
(1976) Biochim. Biophys. Acta 429, 546-554.
Huseby, N.-E. (1977) Biochim. Biophys. Acta 483,46-56.
Hirata, E., Inoue, M. & Morino, Y. (1984) J. Biochem.
Tokyo 96, 289-297.
Wenham, P. R., Horn, D. B. & Smith, A. F. (1986) Clin.
Chim. Acta 160, 223-233,
Wenham, P. R., Horn, D. B. & Smith, A. F. (1982) Clin.
Chim. Acta 124, 303-313.
Huseby, N.-E. & Vik, T. (1978) Clin. Chim. Acta AS, 385-
392.
Ratanasavanh, D., Tazi, A., Gaspart, E., Jacquier, A.,
Notier, D., Galteau, M. M: & Siest, G. (1982) In: Gamma-
glutamyltransferases, Advances in Biochemical Pharma-
cology, 3rd Series (Siest, G. & Heusghem, C., eds.) pp.
93-103, Paris, Masson Publ.
Huseby, N.-E. (1978) Biochim. Biophys. Acta 552, 354-
362.
Crofton, R M. & Smith, A. F. (1981) Clin. Chem. 27,
860-866.
Jung, K. & Wischke, U. W. (1984) Clin. Chem. 30, 856-
859.
Sanderink, G. J., Artur, Y. & Siest, G. (1987) Rev. Inst.
Pasteur Lyon 20, 185--186.
Artur, Y., Wellman-Bednawska, M., Jacquier, A. & Siest,
G. (1984) Clin. Chem. 30, 631-633.
Watanabe, M., Taketa, K., Izuiiii, M. & Nagashima, H.
(1984) Hepatogastroenterol. 31, 204-207.
Huseby, N.-E. (1982) Clin. Chim. Acta 724, 103-112.
Artur, Y., Wellman-Bednawska, M., Jacquier, A. & Siest,
G. (1984) Clin. Chem. 30, 1318-1321.
Sudo, K. & Kanno, T. (1980) Clin. Chim. Acta 107,
49-58.
Maekawa, M., Sudo, K. & Kanno, t. (1986) Clin. Chim.
Acta 757, 45-54.
Page, E. W., Titus, G., Mohun, G. & Glendening, M. B.
(1961) Am. J. Obstet. Gynecol. 82, 1090-1095.
Kleiner, H., Brouet-Yager, M. (1972) Clin. Chim. Acta 40,
177-180.
Sj holm, I. & Yman, L. (1966) Acta. Pharm. Suecica 3,
389-396.
Rutenburg, A. M., Goldbarg, J. A. & Pineda, E. R (1958)
N. Eng. J. Med. 25P, 469-472.
Pineda, E. P., Goldbarg, J. A., Banks, B. M. & Rutenburg,
A. M. (1960) Gastroenterology 38, 698-712.
Bressler, R., Forsyth, B. R. & Klatskin, G. (1960) J. Lab.
Ciin. Med. 56, 417-430.
Kowlessar, O. B. Haeffner, L. J., Riley, E. M., Sleisenger,
M. H. (1961) Am. J. Med. 37, 231 -237.
Weber, H. (1969) Dtsch. Med. Wochenschr. 94,181-184.
Wolf, R L., Williams, D. & Von Der Muehll, F. (1973)
In: Practical clinical enzymology and biochemical profil-
ing, pp. 118-121, J. Wiley, New York.
Haschen, R. J. (1977) Z. Med. Lab. Diagn. 18, 147-158.
J. Clin. Chem. Clin. Biochem. /Vol. 26,1988 / No. 12
Sanderink et al.: Aminopeptidases, a review 807
167. Neef, L., Nilius, R. & Haschen, R. J. (1979) In: Advances
in Clinical Enzymology (Schmidt, E., Schmidt, F. W.,
Trautschold, I. & Friedel, R., eds.) pp. 299-323, Karger,
Basel.
168. Crofton, P. M., Elton, R. A. & Smith, A. F. (1979) Clin.
Chim. Acta PA, 263-275.
169. Artur, Y. & Gouy, D. (1985) In: Examens de laboraloire
et medicaments (Siest, G., Galteau, M. M., Schiele, F. &
Henny, J., eds.) pp. 110—120, Expansion Scientifique
Fran$aise, Paris.
170. Beier, L., Beier, I. & Haschen, R. J. (1969) Clin. Chim.
Acta 24, 405-410.
171. Schlaeger, R. & Kattermann, R. (1971) Clin. Chim. Acta
33, 13-19.
172. Arturson, G., Beckman, L. & Persson, B. H. (1967) Nature
214, 1252-1253.
173. Rundle, A. T. & Sudell, B. (1973) Clin. Chim. Acta 44,
377-384.
174. Philipps, R. W. & Manildi, E. R. (1974) Cancer 34, 350-
357.
175. Pancheva-Haschen, R. & Haschen, R. J. (1986) Enzyme
36, 179-186.
176. Chapman, L., Burrows-Peakin, R., Jowett, T. P., Rege, V.
P. & Silk, E. (1973) Clin. Chim. Acta 47, 89-92.
177. Majkic-Singh, N., Vukovic, A., Spasic, S., Ruzic, A., Sto-
janov, M. & Berkes, I. (1982) Clin. Biochem. 15, 152-
153.
178. Christensen, A., Froshov, D. & Fylling, P. (1974) Acta
Endocrinol. 77, 344-355.
179. Günther, R., Landgraf, R. & Koppe, L (1985) Zbl. Gy-
näkol. 707, 1178-1185.
180. Chard, T. (1987) Ann. Clin. Biochem. 24, 435-439.
181. Mizutani, S., Akiyama, H., Kurauchi, O., Taira, H., Nar-
ita, O. & Tomoda, Y. (1985) Arch. Gynecol. 236, 165-
172.
182. Mizutani, S., Yamada, R., Kurauchi, O., Ito, Y, Narita,
O. & Tomoda, Y (1987) Arch. Gynecol. 240, 27-31.
183. Kalinkov, D. & Bucholz, R. (1980) Am. J. Obstet. Gy-
necol. 138, 1148-1151.
184. Perrault, C, Peynet, J., Legrand, A. & Thuillier, F. (1983)
Ann. Biol. Clin. 41, 222-223.
185. Kanda, S., Nakamura, S. & Kanno, T. (1987) Clin.
Biochem. 20, 53 — 56.
Dr. Y Artur
Laboratoire du Centre de Medecine Preventive
2, Avenue du Doyen J. Parisot
B.P. 7
F-54501 Vandoeuvre-les-Nancy Cedex
J. Clin. Chem. Clin. Biochem. /Vol. 26,1988 /No. 12

